Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Role of TLRs in Anti-cancer Immunity and Tumor Rejection
Zuzanna Urban‐Wójciuk, Mohd M. Khan, Benjamin L. Oyler, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 260

Showing 1-25 of 260 citing articles:

Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity
Tianhao Duan, Yang Du, Changsheng Xing, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 491
Cervical cancer in low and middle‑income countries (Review)
Rodney Hull, Mzwandile Mbele, Tshepiso J. Makhafola, et al.
Oncology Letters (2020) Vol. 20, Iss. 3, pp. 2058-2074
Open Access | Times Cited: 339
Exploring the next generation of antibody–drug conjugates
Kyoji Tsuchikama, Yasuaki Anami, Summer Y. Y. Ha, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 3, pp. 203-223
Open Access | Times Cited: 184
Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside
Darleny Y. Lizardo, Chaoyuan Kuang, Suisui Hao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2020) Vol. 1874, Iss. 2, pp. 188447-188447
Open Access | Times Cited: 152
Recent Advances in Oligonucleotide Therapeutics in Oncology
Haoyu Xiong, Rakesh N. Veedu, Sarah D. Diermeier
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 7, pp. 3295-3295
Open Access | Times Cited: 148
Myeloid cell-targeted therapies for solid tumours
Sangeeta Goswami, Swetha Anandhan, Deblina Raychaudhuri, et al.
Nature reviews. Immunology (2022) Vol. 23, Iss. 2, pp. 106-120
Closed Access | Times Cited: 146
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity
Shelley E. Ackerman, Cecelia I. Pearson, Joshua D. Gregorio, et al.
Nature Cancer (2020) Vol. 2, Iss. 1, pp. 18-33
Open Access | Times Cited: 140
Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes
Samuel I. Kim, Christopher R. Cassella, Katelyn T. Byrne
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 123
Delivery of STING agonists for adjuvanting subunit vaccines
Simon Van Herck, Bing Feng, Li Tang
Advanced Drug Delivery Reviews (2021) Vol. 179, pp. 114020-114020
Open Access | Times Cited: 117
Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer
Christian Rolfo, Elisa Giovannetti, Pablo Martínez, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 86
Context-dependent functions of pattern recognition receptors in cancer
Si Ming Man, Brendan J. Jenkins
Nature reviews. Cancer (2022) Vol. 22, Iss. 7, pp. 397-413
Closed Access | Times Cited: 84
Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
Haowei Sun, Yingmei Li, Peng Zhang, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 70
Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal antitumor immunity
Yongbin Choi, Jake Lichterman, Laura Coughlin, et al.
Science Immunology (2023) Vol. 8, Iss. 81
Open Access | Times Cited: 67
New immune cell engagers for cancer immunotherapy
Aurore Fenis, Olivier Demaria, Laurent Gauthier, et al.
Nature reviews. Immunology (2024) Vol. 24, Iss. 7, pp. 471-486
Closed Access | Times Cited: 65
Toll-like receptor-guided therapeutic intervention of human cancers: molecular and immunological perspectives
Suprabhat Mukherjee, Ritwik Patra, Payam Behzadi, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 63
Harnessing innate immune pathways for therapeutic advancement in cancer
An-Kang Hu, Li Sun, Hao Lin, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 54
Ongoing Clinical Trials of Nonviral siRNA Therapeutics
Eshan A. Narasipura, Rachel VanKeulen-Miller, Yutian Ma, et al.
Bioconjugate Chemistry (2023) Vol. 34, Iss. 7, pp. 1177-1197
Closed Access | Times Cited: 43
Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy
Shuyan He, Lu Zheng, Chunjian Qi
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 2
The Crosstalk Between Hippo-YAP Pathway and Innate Immunity
Shuai Wang, Lili Zhou, Li Ling, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 115
Immunogenic cell death in colon cancer prevention and therapy
Hang Ruan, Brian J. Leibowitz, Lin Zhang, et al.
Molecular Carcinogenesis (2020) Vol. 59, Iss. 7, pp. 783-793
Open Access | Times Cited: 95
FcγR engagement reprograms neutrophils into antigen cross-presenting cells that elicit acquired anti-tumor immunity
Vijayashree Mysore, Xavier Culleré, Joseph Mears, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 83
Tumor-Associated Macrophages: A Potential Target for Cancer Therapy
Yifan Tan, Min Wang, Yang Zhang, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 82
Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions
Katrin Pansy, Barbara Uhl, Jelena Krstić, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13311-13311
Open Access | Times Cited: 82
The role of toll‐like receptor 4 (TLR4) in cancer progression: A possible therapeutic target?
Bahareh Kashani, Zahra Zandi, Atieh Pourbagheri‐Sigaroodi, et al.
Journal of Cellular Physiology (2020) Vol. 236, Iss. 6, pp. 4121-4137
Closed Access | Times Cited: 76
MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma
Ricardo Azevedo, Einav Shoshan, Shanzhi Whang, et al.
OncoImmunology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 72
Page 1 - Next Page

Scroll to top